Verteporfin: A Light Activated Drug for the Treatment of Wet Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is a medical condition which may result in blurred or no vision in the center of the visual field because of damage to the macula. The macula is the part of the retina responsible for central vision and visual acuity. There are two forms of AMD - wet and dry. Wet AMD, also called neovascular or exudative AMD, is a more serious condition caused by abnormal blood vessel growth under the retina. These new blood vessels are very fragile and often leak blood and fluid, rapidly destroying vision. Wet AMD accounts for approximately 10-15% of all AMD cases but is responsible for 90% of severe vision loss associated with AMD.

Mechanism of Action of Verteporfin Therapy

Verteporfin is a light activated drug used to treat wet AMD via a procedure called photodynamic therapy (PDT). Verteporfin is a photosensitizing agent that is injected intravenously and travels through the body. It selectively accumulates in the abnormal new blood vessels under the retina, the site of wet AMD. A non-thermal laser light is then applied directly to the eye for a precise period. When the laser light activates the verteporfin, it produces a photochemical reaction that damages the abnormal blood vessels with very little effect on normal surrounding tissues. This seals off the leaky blood vessels and prevents further damage to the retina from fluid and blood leakage.

Clinical Trial Results Demonstrating Efficacy

The efficacy of verteporfin PDT was established in two pivotal randomized controlled clinical trials - the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study and the Verteporfin in Photodynamic Therapy (VIP) Study. The TAP study randomized subjects with subfoveal choroidal neovascularization to receive either verteporfin PDT plus best available therapy or placebo plus best available therapy. At 3 years, verteporfin PDT stabilized or improved vision in 41% of subjects compared to 28% for placebo. The VIP study also found that verteporfin PDT was more effective than placebo in preventing severe vision loss over 24 months. Based on these clinical trials, verteporfin PDT became the first FDA approved treatment for wet AMD in 2000.

Long-Term Follow up Studies Confirming Durability of Effect

Several long-term follow up studies were conducted to assess the long-term efficacy and safety profile of repeated verteporfin PDT treatments over 5-10 years. The TAP, VIP, and other extension studies found that verteporfin PDT maintained its benefits for slowing vision loss in wet AMD compared to natural disease progression or previous standard treatments like laser photocoagulation alone. Visual acuity outcomes were maintained in approximately 40% of patients over 10 years with re-treatment as needed. Safety was also established, with no new adverse effects observed with long-term repeated use. These studies demonstrated that verteporfin PDT could provide long-lasting benefits for stabilizing vision in wet AMD when administered as pro re nata (as needed) based on disease activity.

Combination Therapy with Anti-VEGF Drugs

While verteporfin PDT remained the mainstay of treatment for over a decade after its approval, newer anti-vascular endothelial growth factor (anti-VEGF) intravitreal injection drugs like ranibizumab and aflibercept have now become the recommended first-line treatment for wet AMD instead. Anti-VEGF drugs are better able to prevent fluid leakage, abnormal vessel growth, and rapid recurrent neovascularization compared to PDT alone. However, some patients still require or prefer verteporfin PDT due to contraindications to anti-VEGF drugs or suboptimal response. Combination therapy using verteporfin PDT along with intravitreal anti-VEGF injections has also been shown to provide enhanced visual outcomes beyond either treatment alone in some clinical trials. So verteporfin PDT retains continued usefulness in combination or refractory disease settings.

Current Role and Guidelines for Use

The current role of verteporfin PDT is as an alternative or adjunct to anti-VEGF drugs according to evidence-based clinical practice guidelines by the American Academy of Ophthalmology and other expert ophthalmic organizations. Indications for verteporfin PDT include:

- As primary treatment if anti-VEGF injections are contraindicated
- As adjuvant treatment with anti-VEGF injections for large lesion size or poor initial response
- For polypoidal choroidal vasculopathy, a subtype associated with Asian ethnicity
- Recurrent or persistent leakage despite multiple effective anti-VEGF injections

Proper patient selection based on lesion type and location as well as need for a test-and-treat approach remains important for optimizing visual outcomes with verteporfin PDT. Overall it plays a valuable niche role for certain wet AMD presentations where anti-VEGF monotherapy may not provide the best results.

Verteporfin PDT was the first effective therapy for wet AMD and remained the standard of care for over a decade after its approval based on results from multiple long-term clinical trials. While now considered an adjunct rather than first-line therapy, it retains utility for certain challenging cases due to its favorable safety profile and different mechanism of action compared to anti-VEGF drugs. With proper patient selection and use in combination or salvage settings, verteporfin photodynamic therapy continues to benefit many wet AMD patients.

Get This Report in Japanese Language -ヴェルテポルフィン市場

Get This Report in Korean Language -베르테포르핀 시장

About Author:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )